Strategic consulting firm serving the life sciences industry, with operations across the US & Europe; Specialized expertise in oncology, CNS, & rare diseases
Medical comms that get deployed to the field often become detached from the core strategy that initiated them. For #MedicalAffairs, that's a problem. Here's what to do about it >> https://t.co/IaCqOoTft1
On May 13, Blue Matter hosted a roundtable discussion with 27 senior biopharma leaders in the Boston area. Now, you can read a summary of these open and insightful conversations: https://t.co/NLjCtS0Yrk
#biotech#pharmaceuticals#biopharma#BlueMatter
Our team recently attended the ISPOR 2026 meeting in Philadelphia. Here are 5 key themes they saw at the conference >> https://t.co/mgBBJxoRqv
#HEOR#RWE#HealthEconomics#biotech#pharmaceuticals
How can you drive access & reimbursement success for a cell / gene therapy? This new article explains why CGT reimbursement is different from specialty pharma, & offers some key success factors for manufacturers. >> https://t.co/m05ZDy2BAr
#biotech#pharmaceuticals#celltherapy
Recently, our team attended the MAPS Americas meeting in Denver. Here are 5 key themes from the discussions there >> https://t.co/DJG8nNbwRe
#medicalaffairs#biotech#pharmaceutical
What was once a relatively stable βbuy-and-billβ ecosystem for physician-administered drugs is being significantly reshaped by a range of market and policy factors. Read our latest paper to learn more about them.
https://t.co/WiNfXzJxZj